Citations

Clear

941 citation(s) found for "Tan, MH".

Utility of CT and MRI in Cardiac Electrophysiology
Bugenhagen, Scott M. , Kolluri, Nikhil , Tan, Nicholas Y. , Morris, Michael F. , Bugenhagen, Scott , Rajiah, Prabhakar , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | August 8, 2024 | Volume: 44 | Issue: 9 | Pages: No page available

10.1148/rg.230222 | PMID 39115996 Get It

Federated Learning for Enhanced ECG Signal Classification with Privacy Awareness
Nguyen, Linh Thi Hoai , Zhang, Lan , Nguyen, Tuy Tan , Phan, Quoc Bao , Nguyen, Linh, Bui, Ngoc Thang , Nguyen, Dinh C.

Mayo Clinic

No container title available | August 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.36227/techrxiv.172296272.25318883/v1 Get It

This paper presents a novel approach for classifying electrocardiogram (ECG) signals in healthcare applications using federated learning and stacked convolutional neural networks (CNNs). Our innovative technique leverages the distributed nature of federated learning to collaboratively train a highperformance model while preserving data privacy on local devices. We propose a stacked CNN architecture tailored for ECG data, effectively extracting discriminative features across different temporal scales. The evaluation confirms the strength of our approach, culminating in a final model accuracy of 98.6% after 100 communication rounds, significantly exceeding baseline performance. This promising result paves the way for accurate and privacy-preserving ECG classification in diverse healthcare settings, potentially leading to improved diagnosis and patient monitoring.
Resection versus resection with ablation: Analysis from the colorectal liver operative metastasis international collaborative
Mainali, Bigyan B. , Valenzuela, Cristian D. , Moaven, Omeed , Piccolo, Nico R. Del, Corvera, Carlos U. , Wisneski, Andrew D. , Zarandi, Nima Pourhabibi , Dourado, Justin , Shen, Perry , Del Piccolo, Nico R, Shen, Perry , Moaven, Omeed , Stauffer, John , Cheung, Tan To , Cha, Charles , Russell, Gregory B.

Mayo Clinic

Journal of Surgical Oncology | August 5, 2024 | Volume: 130 | Issue: 3 | Pages: 516-522

10.1002/jso.27789 | PMID 39099202 Get It

AbstractBackgroundThermal ablation has recently become a key therapy for the treatment of colorectal liver metastasis (CLM). However, the role of ablation in combination with resection has not yet been firmly established. We hypothesize that in patients with CLM, those who undergo liver resection with ablation (RA) have similar outcomes compared with those who undergo liver resection only.MethodsWe reviewed a multicenter international database of 906 surgical procedures for CLM from 5 high volume hepatobiliary surgical units. Patients undergoing RA (n = 63) were matched based on the number of lesions and tumor size using a 1:1 balanced propensity score analysis with those having resection only (n = 63). Our primary outcomes were overall survival (OS) and disease‐free survival (DFS).ResultsThe mean age of our cohort was 58 ± 11 years, with 43% females. With a median follow‐up of 70.8 months, patients in the resection and RA group had a median OS of 45.1 and 54.8 months (p = 0.71), respectively. The median DFS was 22.7 and 14.2 months (p = 0.045), respectively. Using a multivariate Cox proportional hazards regression model, the treatment approach was not associated with OS (p = 0.94) or DFS (p = 0.059). A higher number of lesions is independently associated with worse DFS (hazard ratio: 1.12, p < 0.01). When there was disease recurrence, the region of recurrence was similar between the RA versus resection only groups (p = 0.27), but there was a shorter time to recurrence in the RA group (p = 0.002).ConclusionFor CLM, the treatment approach was not significantly associated with OS or DFS, while tumor biology likely played an important role. Prospective research on the quality and effectiveness of thermal ablation combined with hepatic resection is warranted.
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey
Banez, Marisela Tan , Atienza, Sol , Butts, Allison R, Derba, Megan, Dicke, Katie, Haverstick, Kimberly, Heron, Bernadette B. , Cimino, Sarah K, Loop, Matthew Shane , Hough, Shannon , Merten, Julianna A., Taucher, Kate D, Zhang, J, Butts, Allison , Shah, Vishal , Mahmoudjafari, Zahra , Moore, Donald C. , Shah, Vishal

Mayo Clinic

Journal of Oncology Pharmacy Practice | August 2, 2024 | Volume: 31 | Issue: 4 | Pages: 517-527

10.1177/10781552241265280 | PMID 39091073 Get It

Introduction The treatment of cancer is associated with high risk for toxicity and high cost. Strategies to enhance the value, quality, and safety of cancer care are often managed independently of one another. Oncology stewardship is a potential framework to unify these efforts and enhance outcomes. This landscape survey establishes baseline information on oncology stewardship in the United States. Methods The Hematology/Oncology Pharmacy Association (HOPA) distributed a 38-item survey composed of demographic, institutional, clinical decision-making, support staff, metrics, and technology sections to 675 HOPA members between 9 September 2022 and 9 October 2022. Results Most organizations (78%) have adopted general pharmacy stewardship practices; however, only 31% reported having established a formalized oncology stewardship team. More than 70% of respondents reported implementation of biosimilars, formulary management, and dose rounding as oncology stewardship initiatives in both inpatient and outpatient settings. Frequently cited barriers to oncology stewardship included lack of clinical pharmacist availability (74%), lack of oncology stewardship training (62%), lack of physician/provider buy-in (32%), and lack of cost-saving metrics (33%). Only 6.6% of survey respondents reported their organization had defined “value in oncology.” Lack of a formalized stewardship program was most often cited (77%) as the rationale for not defining value. Conclusions Less than one-third of respondents have established oncology stewardship programs; however, most are providing oncology stewardship practices. This manuscript serves as a call to action for stakeholders to work together to formalize oncology stewardship programs that optimize value, quality, and safety for patients with cancer.
Combined Phacoemulsification and Hydrus Microstent Implantation in Asian Eyes With Moderate-to-Severe Normal Tension Glaucoma—12-Month Outcomes
Chen, Elizabeth Jiahui , Chee, Wai Kitt, Chua, Chun Hau, Yip, Vivien Cherng Hui, Ang, Bryan C H , Betzler, Bjorn Kaijun , Yip, Leonard Wei Leon

Mayo Clinic

Journal of Glaucoma | July 31, 2024 | Volume: 33 | Issue: 11 | Pages: 855-861

10.1097/ijg.0000000000002475 | PMID 39083013 Get It

Précis: This study reports 12-month outcomes of combined phacoemulsification and Hydrus Microstent implantation in Asian eyes with moderate-to-severe normal tension glaucoma (NTG), demonstrating a significant reduction in glaucoma medications with an excellent intra and postoperative safety profile. Objective: To evaluate the 12-month safety and efficacy outcomes of combined phacoemulsification and Hydrus Microstent (Ivantis Inc.) implantation in Asian eyes with moderate to severe NTG. Methods: Retrospective study of consecutive surgeries performed from August 2019 to August 2021 in a single tertiary eye centre in Singapore. Outcome measures included a reduction in intraocular pressure (IOP), number of glaucoma medications, and intra and postoperative complications. Results: Data from 21 eyes of 21 subjects were analyzed. All subjects were ethnic Chinese, and the majority were males (14, 66.7%). At baseline, the mean IOP was 13.3 (2.3) mm Hg, all eyes had a Humphrey visual field mean deviation of ≥−6 dB [mean: −13.9 (4.3) dB], and all eyes were on at least one glaucoma medication. There was no statistically significant reduction in IOP at all time points compared with baseline (all P > 0.05). However, the median number of medications was reduced from 2 to 0 at all time points, up to postoperative month (POM) 12 (all P < 0.001). There were no intraoperative complications. No eyes underwent secondary glaucoma procedures nor lost any Snellen line of visual acuity by POM12. One (4.8%) eye experienced numerical hypotony at postoperative day 1, which resolved conservatively. Two (9.5%) eyes underwent laser iridoplasty for stent occlusion by iris. There was no deterioration in Humphrey visual field mean deviation at POM12 compared with baseline (n = 20, P > 0.05). Conclusion: Combined phacoemulsification and Hydrus Microstent implantation were effective in reducing medication burden in Asian eyes with moderate to severe NTG, up to 12 months postoperatively.
Pretreatment predictors of very poor clinical outcomes in medium vessel occlusion stroke patients treated with mechanical thrombectomy
Yedavalli, Vivek , Salim, Hamza , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Kühn, Anna Luisa, Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil, Essibayi, Muhammed Amir , Puri, Ajit S , Dyzmann, Christian , Colasurdo, Marco , Barreau, Xavier , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S., Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Liebeskind, David S. , Henninger, Nils , Tan, Benjamin Yq , Cancelliere, Nicole M , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Clarençon, Frédéric , Siegler, James E , Nguyen, Thanh N , Gonzalez, Nestor R , Pedicelli, Alessandro , Alexandre, Andrea M , Guenego, Adrien , Dmytriw, Adam A , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Salim, Hamza , Regenhardt, Robert W , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Rouchaud, Aymeric , Colasurdo, Marco , Varela, Ricardo , Musmar, Basel , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Bernstock, Joshua D. , Fiehler, Jens , Sheth, Sunil A , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

International Journal of Stroke | July 30, 2024 | Volume: 19 | Issue: 10 | Pages: 1123-1133

10.1177/17474930241270524 | PMID 39075759 Get It

Background: Acute ischemic stroke (AIS) from primary medium vessel occlusions (MeVO) is a prevalent condition associated with substantial morbidity and mortality. Despite the common use of mechanical thrombectomy (MT) in AIS, predictors of poor outcomes in MeVO remain poorly characterized. Methods: In this prospectively collected, retrospectively reviewed, multicenter, multinational study, data from the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry were analyzed. The study included 1568 patients from 37 academic centers across North America, Asia, and Europe, treated with MT, with or without intravenous tissue plasminogen activator (IVtPA), between September 2017 and July 2021. Results: Among the 1568 patients, 347 (22.2%) experienced very poor outcomes (modified Rankin score (mRS), 5–6). Key predictors of poor outcomes were advanced age (odds ratio (OR): 1.03; 95% confidence interval (CI): 1.02 to 1.04; p < 0.001), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (OR: 1.07; 95% CI: 1.05 to 1.10; p < 0.001), pre-operative glucose levels (OR: 1.01; 95% CI: 1.00 to 1.02; p < 0.001), and a baseline mRS of 4 (OR: 2.69; 95% CI: 1.25 to 5.82; p = 0.011). The multivariable model demonstrated good predictive accuracy with an area under the receiver-operating characteristic (ROC) curve of 0.76. Conclusions: This study demonstrates that advanced age, higher NIHSS scores, elevated pre-stroke mRS, and pre-operative glucose levels significantly predict very poor outcomes in AIS-MeVO patients who received MT. These findings highlight the importance of a comprehensive risk assessment in primary MeVO patients for personalized treatment strategies. However, they also suggest a need for cautious patient selection for endovascular thrombectomy. Further prospective studies are needed to confirm these findings and explore targeted therapeutic interventions.
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)—Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD)
Chang, George J. , Gunn, Heather, Barber, Anne K., Lowenstein, Lisa M. , Dohan, Daniel , Dockter, Travis , Tan, Angelina D., Dueck, Amylou C. , Chow, Selina , Neuman, Heather B. , Finlayson, Emily , Investigators, on behalf of the OPTI-Surg, Dueck, A. C. , Gunn, Heather J., Barber, Anne, Broering, Jeanette M. , Investigators, on behalf of the OPTI-Surg

Mayo Clinic

Annals of Surgery | July 29, 2024 | Volume: 280 | Issue: 4 | Pages: 623-632

10.1097/sla.0000000000006458 | PMID 39069901 Get It

Objective: To assess the effect of a practice-level preoperative frailty screening and optimization toolkit (OPTI-Surg) on postoperative functional recovery and complications in elderly cancer patients undergoing major surgery. Background: Frailty is common in older adults. It increases the risk of poor postoperative functional recovery and complications. The potential for a practice-level screening/optimization intervention to improve outcomes is unknown. Methods: Thoracic, gastrointestinal, and urologic oncological surgery practices within the National Cancer Institute Community Oncology Research Program (NCORP) were randomized 1:1:1 to usual care (UC), OPTI-Surg, or OPTI-Surg with an implementation coach. OPTI-Surg consisted of the Edmonton Frail Scale and guided recommendations for referral interventions. Patients 70 years old or above undergoing curative intent surgery were eligible. The primary outcome was 8 weeks postoperative function (kcal/wk). The key secondary outcome was complications within 90 days. Mixed models were used to compare UC to the 2 OPTI-Surg arms combined. Results: From July 2019 to September 2022, 325 patients were enrolled in 29 practices. One hundred ninety-nine (64 UC, 135 OPTI-Surg) and 279 (78 UC, 201 OPTI-Surg) were evaluable for primary and secondary analysis, respectively. UC and OPTI-Surg patients did not significantly differ in total caloric expenditure (2.2 UC, 2.0 OPTI-Surg) after adjusting for baseline function (P=0.53). UC and OPTI-Surg patients did not significantly differ in postoperative complications (25.6% UC, 35.3% OPTI-Surg, P=0.5). Conclusions: Frailty assessment was successfully performed, but the OPTI-Surg intervention did not improve postoperative function nor reduce postoperative complications compared with UC. Future analysis will explore practice-level factors associated with toolkit implementation and the differences between the coaching and noncoaching arms.
Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis
Tan, Qi , Wellmerling, Jack , Song, Shengren, Dresler, Sara R. , Meridew, Jeffrey A., Choi, Kyoung Moo , Li, Yong , Prakash, Y. S. , Tschumperlin, Daniel J. , Wellmerling, Jack H, Choi, Kyoung M, Prakash, Y S

Mayo Clinic

JCI Insight | July 16, 2024 | Volume: 9 | Issue: 16 | Pages: No page available

10.1172/jci.insight.175290 | PMID 39012710 Get It

Fibrosis in the lung is thought to be driven by epithelial cell dysfunction and aberrant cell-cell interactions. Unveiling the molecular mechanisms of cellular plasticity and cell-cell interactions is imperative to elucidating lung regenerative capacity and aberrant repair in pulmonary fibrosis. By mining publicly available RNA-Seq data sets, we identified loss of CCAAT enhancer-binding protein alpha (CEBPA) as a candidate contributor to idiopathic pulmonary fibrosis (IPF). We used conditional KO mice, scRNA-Seq, lung organoids, small-molecule inhibition, and potentially novel gene manipulation methods to investigate the role of CEBPA in lung fibrosis and repair. Long-term (6 months or more) of Cebpa loss in AT2 cells caused spontaneous fibrosis and increased susceptibility to bleomycin-induced fibrosis. Cebpa knockout (KO) in these mice significantly decreased AT2 cell numbers in the lung and reduced expression of surfactant homeostasis genes, while increasing inflammatory cell recruitment as well as upregulating S100a8/a9 in AT2 cells. In vivo treatment with an S100A8/A9 inhibitor alleviated experimental lung fibrosis. Restoring CEBPA expression in lung organoids ex vivo and during experimental lung fibrosis in vivo rescued CEBPA deficiency–mediated phenotypes. Our study establishes a direct mechanistic link between CEBPA repression, impaired AT2 cell identity, disrupted tissue homeostasis, and lung fibrosis.
Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy
Mehanna, Raja , Kumar, Kishore R. , Oosterbaan, Annelien M., Post, Bart , Ross, Owen A. , Piemonte, Maria Elisa Pimentel , Fraix, Valérie , Moro, Elena , Tan, Eng‐King , Savica, Rodolfo , Force, on behalf of the EOPD Task, Oosterbaan, Annelien , Ross, Owen A , Kumar, Kishore Raj , Pimentel Piemonte, Maria Elisa , Oosterbaan, Annelien M , Śmiłowska, Katarzyna , Fleisher, Jori , Alcalay, Roy N. , Marras, Connie , Force, on behalf of the EOPD Task

Mayo Clinic

Journal of Parkinson’s Disease | July 12, 2024 | Volume: 14 | Issue: 6 | Pages: 1277-1282

10.3233/jpd-240088 | PMID 38995803 Get It

Pregnancy in women with early-onset Parkinson’s disease (PD) is likely to have a higher frequency given the trend toward increasing maternal age, thus resulting in a greater overlap time between childbearing age and PD risk. Deep brain stimulation (DBS) therapy is nowadays offered to PD patients at earlier stage of the disease, when women can still be pre-menopausal. However, few data are available about DBS safety during pregnancy. From a review of the available literature, only one article was published on this topic so far. Therefore, we have developed a clinical consensus on the safety of DBS during pregnancy in PD patients.
RNA‐sequencing reveals differential fibroblast responses to bleomycin and pneumonectomy
Wellmerling, Jack , Dresler, Sara R. , Meridew, Jeffrey A., Choi, Kyoung Moo , Tschumperlin, Daniel J. , Tan, Qi , Wellmerling, Jack H, Choi, Kyoung M

Mayo Clinic

Physiological Reports | July 12, 2024 | Volume: 12 | Issue: 13 | Pages: No page available

10.14814/phy2.16148 | PMID 38991987 Get It

AbstractPulmonary fibrosis is characterized by pathological accumulation of scar tissue in the lung parenchyma. Many of the processes that are implicated in fibrosis, including increased extracellular matrix synthesis, also occur following pneumonectomy (PNX), but PNX instead results in regenerative compensatory growth of the lung. As fibroblasts are the major cell type responsible for extracellular matrix production, we hypothesized that comparing fibroblast responses to PNX and bleomycin (BLM) would unveil key differences in the role they play during regenerative versus fibrotic lung responses. RNA‐sequencing was performed on flow‐sorted fibroblasts freshly isolated from mouse lungs 14 days after BLM, PNX, or sham controls. RNA‐sequencing analysis revealed highly similar biological processes to be involved in fibroblast responses to both BLM and PNX, including TGF‐β1 and TNF‐α. Interestingly, we observed smaller changes in gene expression after PNX than BLM at Day 14, suggesting that the fibroblast response to PNX may be muted by expression of transcripts that moderate pro‐fibrotic pathways. Itpkc, encoding inositol triphosphate kinase C, was a gene uniquely up‐regulated by PNX and not BLM. ITPKC overexpression in lung fibroblasts antagonized the pro‐fibrotic effect of TGF‐β1. RNA‐sequencing analysis has identified considerable overlap in transcriptional changes between fibroblasts following PNX and those overexpressing ITPKC.